Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Octreotide 100micrograms/1ml solution for injection ampoules
0803043N0AAABAB
|
Octreotide acetate | Octreotide acetate | Malignant Disease and Immunosuppression | 244 |
|
Octreotide 500micrograms/1ml solution for injection ampoules
0803043N0AAACAC
|
Octreotide acetate | Octreotide acetate | Malignant Disease and Immunosuppression | 227 |
|
Octreotide 30mg inj vials
0803043N0AAAFAF
|
Octreotide acetate | Octreotide acetate | Malignant Disease and Immunosuppression | 104 |
|
Octreotide 20mg inj vials
0803043N0AAAGAG
|
Octreotide acetate | Octreotide acetate | Malignant Disease and Immunosuppression | 90 |
|
Octreotide 100micrograms/1ml inj pre-filled syringes
0803043N0AAAPAP
|
Octreotide acetate | Octreotide acetate | Malignant Disease and Immunosuppression | 88 |
|
Octreotide 50micrograms/1ml solution for injection ampoules
0803043N0AAAAAA
|
Octreotide acetate | Octreotide acetate | Malignant Disease and Immunosuppression | 72 |
|
Octreotide 50micrograms/1ml inj pre-filled syringes
0803043N0AAANAN
|
Octreotide acetate | Octreotide acetate | Malignant Disease and Immunosuppression | 57 |
|
Octreotide 1mg/5ml solution for injection vials
0803043N0AAADAD
|
Octreotide acetate | Octreotide acetate | Malignant Disease and Immunosuppression | 56 |
|
Octreotide 500micrograms/1ml solution for injection vials
0803043N0AAAMAM
|
Octreotide acetate | Octreotide acetate | Malignant Disease and Immunosuppression | 24 |
|
Octreotide 10mg inj vials
0803043N0AAAEAE
|
Octreotide acetate | Octreotide acetate | Malignant Disease and Immunosuppression | 19 |
|
Octreotide 500micrograms/1ml inj pre-filled syringes
0803043N0AAAQAQ
|
Octreotide acetate | Octreotide acetate | Malignant Disease and Immunosuppression | 17 |
|
Octreotide 100micrograms/1ml solution for injection vials
0803043N0AAALAL
|
Octreotide acetate | Octreotide acetate | Malignant Disease and Immunosuppression | 11 |
|
Octreotide 50micrograms/1ml solution for injection vials
0803043N0AAAKAK
|
Octreotide acetate | Octreotide acetate | Malignant Disease and Immunosuppression | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.